Sanjivani Paranteral Ltd

Sanjivani Paranteral Ltd’s shares declined sharply to a fresh 52-week low of Rs.161 on 3 February 2026, marking a significant downturn amid a broader market rally. The stock has underperformed its sector and the wider market, reflecting a series of financial and valuation concerns that have weighed on investor sentiment.

Sanjivani Paranteral Ltd’s shares declined sharply to a fresh 52-week low of Rs.162.1 on 2 Feb 2026, marking a significant downturn amid broader market pressures and company-specific performance factors. The stock has now recorded a three-day consecutive fall, cumulatively losing 4.74% over this period, underperforming its sector and the broader market indices.

Sanjivani Paranteral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Sanjivani Paranteral Ltd’s shares declined to a fresh 52-week low of Rs.169 on 21 Jan 2026, marking a significant downturn amid broader market weakness and company-specific performance pressures. The stock has underperformed its sector and the broader market, reflecting a challenging period for the pharmaceuticals and biotechnology firm.

Sanjivani Paranteral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Sanjivani Paranteral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 January 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market standing.

Sanjivani Paranteral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 December 2025, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Sanjiv.Parant., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment follows a detailed review of the company’s quality, valuation, financial trends, and technical indicators, highlighting challenges in sustaining growth amid a demanding market environment.

Sanjivani Paranteral Ltd., a WHO-GMP certified pharmaceutical company specialising in injectables and oral solids, reported a challenging Q2 FY26 with net profit declining to ₹1.64 crores, down 5.20% quarter-on-quarter and 28.70% year-on-year. The micro-cap pharmaceutical player, with a market capitalisation of ₹223.00 crores, faced headwinds from contracting revenues and compressed margins during the September 2025 quarter. The stock has reacted negatively to the results, trading at ₹181.85 as of November 18, 2025, down 3.86% and significantly below its 52-week high of ₹396.95.

Sanjivani Paranteral has reached a new 52-week low, reflecting a notable decline in its stock performance. The company has underperformed its sector and experienced consecutive losses, while also showing high volatility. Despite these challenges, it maintains strong management efficiency and healthy long-term growth in net sales and operating profit.

Sanjivani Paranteral has hit a new 52-week low, reflecting a significant downturn in its stock performance. The company has underperformed its sector and experienced high volatility, trading below key moving averages. Despite these challenges, it maintains strong management efficiency and increased promoter confidence in its future.

Sanjivani Paranteral has hit a new 52-week low of Rs. 170, reflecting a notable decline amid broader market gains. The stock has underperformed its sector and is trading below key moving averages, raising concerns despite some positive indicators like increased promoter confidence and growth in net sales and operating profit.

Sanjivani Paranteral has reached a new 52-week low, reflecting a significant downturn in its stock performance. The company has underperformed its sector and experienced consecutive declines. Despite these challenges, it maintains strong management efficiency and has reported healthy long-term growth in net sales and operating profit.